Structure and activities of pharmacy and therapeutics committees among public hospitals in South Africa; findings and implications

Expert Review of Clinical Pharmacology

Volumn 10, Issue 11, 2017, Pages 1273-1280

  Matlala, Moliehi ^a   Gous, Andries GS ^a   Godman, Brian ^b,c,d   Meyer, Johanna C ^a  

^a SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

Author keywords

hospitals; pharmacovigilance; Pharmacy and therapeutics committees; rational use of medicines; South Africa

Indexed keywords

ADVERSE DRUG REACTION; ARTICLE; BLOOD BANK; DECISION MAKING; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED PRACTICE; EXPLORATORY RESEARCH; HEALTH CARE COST; HOSPITAL; HUMAN; LABORATORY; MEDICAL SPECIALIST; MEDICATION ERROR; ORGANIZATIONAL POLICY; ORGANIZATIONAL STRUCTURE; PHARMACIST; PHARMACOECONOMICS; PHARMACY AND THERAPEUTICS COMMITTEE; PRACTICE GUIDELINE; PROTOCOL COMPLIANCE; PUBLIC HOSPITAL; PUBLICATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SEMI STRUCTURED INTERVIEW; SOUTH AFRICA; TERTIARY CARE CENTER; HOSPITAL PHARMACY; ORGANIZATION AND MANAGEMENT; PROFESSIONAL STANDARD; QUESTIONNAIRE;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DECISION MAKING; FORMULARIES, HOSPITAL; HOSPITALS, PUBLIC; HUMANS; MEDICATION ERRORS; PHARMACISTS; PHARMACY AND THERAPEUTICS COMMITTEE; PHARMACY SERVICE, HOSPITAL; PROFESSIONAL ROLE; SOUTH AFRICA; SURVEYS AND QUESTIONNAIRES;

EID: 85027490273     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1080/17512433.2017.1364625     Document Type: Article

References (52)

1. Bertino J., Pharmacy and therapeutic committees and hospital formulary. In: Waldman SA, Terzic A, editors. Pharmacology and therapeutics principles to practice. Philadelphia, USA: Saunders ELSIEVIER; 2009. p. 1233–1236.
2. Godman B, Malmstrom RE, Diogene E, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8(1):77–94.
3. Bjorkhem-Bergman L, Andersen-Karlsson E, Laing R, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol. 2013;69(Suppl 1):73–78.
4. Spurling GK, Mansfield PR, Montgomery BD, et al. Information from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: a systematic review. PLoS Med. 2010;7(10):e1000352.
5. Civaner M., Sale strategies of pharmaceutical companies in a “pharmerging” country: the problems will not improve if the gaps remain. Health Policy. 2012;106(3):225–232.
6. Fleischman W, Agrawal S, King M, et al. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study. BMJ. 2016;354:i4189.
7. Perlis RH, Perlis CS. Physician payments from industry are associated with greater medicare part D prescribing costs. PloS One. 2016;11(5):e0155474.
8. Salmasi S, Ming LC, Khan TM. Interaction and medical inducement between pharmaceutical representatives and physicians: a meta-synthesis. J Pharm Policy Pract. 2016;9(1):37.
9. Lima-Dellamora E, Caetano R, Gustafsson LL, et al. An analytical framework for assessing drug and therapeutics committee structure and work processes in tertiary Brazilian hospitals. Basic Clin Pharmacol Toxicol. 2014;115:268–276.
10. Hoffmann M. The right drug, but from whose perspective? A framework for analyzing the structure and activities of drug and therapeutics committees. Eur J Clin Pharmacol. 2013;69(1):S79–87.
11. Godman B, Wettermark B, Hoffmann M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9(1):65–83.
12. Laing RO, Hogerzeil HV, Ross-Degnan D. Ten recommendations to improve the use of medicines in developing countries. Health Policy Plan. 2001;16(1):13–20.
13. Weekes LM, Brooks C. Drug and therapeutics committees in Australia: expected and actual performance. Br J Clin Pharmacol. 1996;42:551–557.
14. Sabah BA, Sania AS, Salah IK. Assessment of structure, implementation and activities, Hospital formulary System in Khartoum State Hospitals. J Pharm Biomed Sci. 2012;22(22):1–6.
15. Malmstrom RE, Godman BB, Diogene E, et al. Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol. 2013;4:39.
16. Godman B, Campbell S, Suh HS, et al. Ongoing measures to enhance prescribing efficiency across Europe: implications for other countries. J Health Tech Assess. 2013;1:27–42.
17. World Health organization. 2007. The 60th World Health Assembly Report. Geneva. Available from: http://apps.who.int/gb/ebwha/pdf_files/WHASSA_WHA60-Rec1/E/cover-intro-60-en.pdf (accessed 15 November 2016)
18. American Society of Health-System Pharmacists. Guidelines on the pharmacy and therapeutics committees and the formulary system. Am J Health-Systems Pharm. 2008;65:1272–1283.
19. Mittman N, Knowels S. A survey of pharmacy and therapeutics committees across Canada: scope and responsibilities. Can J Clin Phamacology. 2009;16(1):e171–179.
20. Plet HT, Hallas J, Nielsen GS, et al. Drug and therapeutics committees in Danish hospitals: a survey of organization, activities and drug selection procedures. Basic Clin Pharmacol Toxicol. 2013;112(4):264–269.
21. Puigventos F, Santos-Ramos B, Ortega A, et al. Structure and procedures of the pharmacy and therapeutics committees in Spanish hospitals. Pharm World Sci. 2010;32(6):767–775.
22. Vang C, Tomson G, Kounnavong S, et al. Improving the performance of Drug and Therapeutics Committees in hospitals–a quasi-experimental study in Laos. Eur J Clin Pharmacol. 2006;62(1):57–63.
23. Holloway K, Green T. Drug and therapeutics committees: a practical guide. World Health Organisation; 2003. Available from: http://apps.who.int/medicinedocs/pdf/s4882e/s4882e.pdf (accessed 10 November 2016)
24. Gauteng Province Department of Health. 2013. Guidelines for Implementation of Pharmaceutical and Therapeutics Committee in Gauteng Province. 1st edition. Available from: http://apps.who.int/medicinedocs/documents/s21654en/s21654en.pdf (accessed 10 November 2016)
25. Department of Health. 1996. National Drug Policy for South Africa. Available from: http://apps.who.int/medicinedocs/documents/s17744en/s17744en.pdf (accessed 11 November 2016)
26. Gauteng Province Department of Health. 2004. Implementation of pharmacy and therapeutics committees at all levels. Circular Letter 27. Available from: http://www.treasury.gov.za/publications/annual%20reports/provincial/2005/GT/GP%20-%20Vote%2004%20-%20Health.pdf (accessed 10 November 2016)
27. Republic of South Africa. White paper on National Health Insurance for South Africa: Towards universal coverage. National Department of Health. Government Gazzette No 39506: version 40. 2015 Dec11.
28. Rankin J, Graaff P, Dias V, et al. Analyzing and controlling pharmaceutical expenditure. Chapter 40. In: MDS-3: managing access to medicine and health technologies. Arlington (VA): Management Sciences for Health; 2012. Available from: https://www.msh.org/sites/msh.org/files/mds3-jan2014.pdf
29. Naidoo S, Wand H, Abbai NS, et al. High prevalence and incidence of sexually transmitted infections among women living in Kwazulu-Natal, South Africa. AIDS Res Ther. 2014 Sep 15;11:31.
30. Ramjee G, Abbai NS, Naidoo S. Women and Sexually Transmitted Infections in Africa. Open J Obstetrics Gynecol. 2015;5:385–399.
31. Maimela E, Alberts M, Modjadji SEP, et al. The prevalence and determinants of chronic non-communicable disease risk factors amongst adults in the Dikgale Health Demographic and Surveillance System (HDSS) site, Limpopo Province of South Africa. PloS ONE. 2016;e0147926. DOI:10.1371/journal.pone.0147926
32. Lalkhen H, Mash R. Multimorbidity in non-communicable disease in South African primary healthcare. South Afr Med J. 2015;105(2). Available from: http://www.Scielo.org.za/pdf/samj/v105n2/24pdf (accessed 10 November 2016)
33. Lloyd-Sherlock P, Beard J, Minicuci N, et al. Hypertension among older adults in low- and middle-income countries: prevalence, awareness and control. Int J Epidemiol. 2014;43(1):116–128.
34. Cois A, Day C. Obesity trends and risk factors in the South African adult population. BMC Obesity. 2015;2:42.
35. Gustafsson LL, Wettermark B, Godman B, et al. The ‘wise list’- a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin Pharmacol Toxicol. 2011;108(4):224–233.
36. Ummmuaypornlert A, Kiitikannakorn N. Performance of pharmacy and therapeutics committees of public hospitals in rural Thailand. Mahidol Univ J Pharm Sci. 2014;41(1):11–18.
37. Olson C, Forshaw C, Hogerzeil H. Treatment guidelines and formulary manuals. Chapter 17. In: MDS-3: managing access to medicine and health technologies. Arlington (VA): Management Sciences for Health; 2012. Available from: https://www.msh.org/sites/msh.org/files/mds3-jan2014.pdf
38. Mendelson M, Matsoso M. The South African antimicrobial resistance strategy framework. AMR Control. 2015;54–61. Available from: http://globalhealthdynamics.co.uk/wp-content/uploads/2015/06/08_Mendelson-Matsotso.pdf (accessed 10 November 2016)
39. South Africa Department of Health. 2015. Implementation plan for the antimicrobial resistance strategy framework in South Africa: 2014-2019. Available from: http://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0ahUKEwjkq9O24IrRAhWJNlAKHb7qAgUQFggaMAA&url=http%3A%2F%2Fwww.health.gov.za%2Findex.php%2Fantimicrobial-resistance%3Fdownload%3D1175%3Aimplementation-plan-for-the-antimicrobial-resistance-strategy-framework-in-south-africa-2014-2019&usg=AFQjCNHKDUEmdzqyeLB-i-ZMnz6-W0xDaA&bvm=bv.142059868,d.ZWM (accessed 10 November 2016)
40. Duran-Garcia E, Santos-Ramos B, Puigventos-Latore F, et al. Literature review on the structure and operation of Pharmacy and Therapeutics Committees. Int J Clin Pharm. 2011;33:475–482.
41. Pedersen CA, Schneider PJ, Scheckelhoff GJ. ASHP national survey of pharmacy practice, hospital setting: prescribing and transcribing. Am J Health-Systems Pharm. 2005;62:378–390.
42. Collao JF, Smith F, Barber N. Selection of Medicine in Chilean public hospitals: an exploratory study. BMC Health Serv Res. 2013;13:10. Available from: http://www.biomedicalcentral.com/1472-6963/13/10 (accessed 12 November 2016)
43. Tan EL, Day RO, Brien JE. Drug and Therapeutics Committees- are they fulfilling their potential to improve the quality use of medicines? Int J Pharm Pract. 2003;11:175–181.
44. Spitzer-Lehamann R. Nursing management desk reference: concepts, skills and strategies. Philadephia: W.B. Saunders; 1994.
45. Walsh K. Managing the budget in healthcare professional education. Ann Med Healthc Sci Res. 2016;6(2):71–73.
46. Matusewicz W, Godman B, Pedersen HB, et al. Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755–758.
47. Wettermark B, Pehrsson A, Juhasz-Haverinen M, et al. Financial incentives linked to self-assessment of prescribing patterns: a new approach for quality improvement of drug prescribing in primary care. Qual Prim Care. 2009;17(3):179–189.
48. Terblanché A, Meyer J, Summers RS, Baseline data for the development and evaluation of a structured pharmacovigilance system in Sebokeng Hospital, Gauteng Province. MURIA Conference Anti Infectives. 2016: 5. PV, NCD, DU Studies. Available from: http://muria.nmmu.ac.za/2nd-MURIA-Training-Workshop-and-Symposium,-25-27-J (accessed 12 November 2016)
49. Ortega A, Aquinaqalde A, Lacasa C, et al. Efficacy of an adverse drug reaction electronic reporting system integrated into a hospital information system. Ann Pharmacother. 2008;42(10):1491–1496.
50. Yu-Hsuan Y, Li-Na K, Min-Huei H, et al. Evaluation of the electronic adverse event management system. J Exp Clin Med. 2010;2(6):287–291.
51. Terblanché A, Meyer JC, Summers RS, et al. Impact of a pharmacist-driven pharmacovigilance system in a secondary hospital in the Gauteng Province of South Africa. MURIA 3 2017; 25. Available from: http://muria.mandela.ac.za/muria/media/Store/documents/Abstract%20book%20-%20MURAI%203/MURIA3-AbstractBook-July-2017.pdf (accessed 28 July 2017)
52. Suh D, Opara IR, Agnese WB, et al. Appplication of pharmacoeconomics to formulary decision making in managed care organizations. Am J Manag Care. 2002;8:161–169.